ArticleBiomedical engineering online2025
Influence of m6A regulatory factor related to immune microenvironment on the prognosis of prostate cancer.
Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PC) is an epithelial malignant tumor that occurs in the prostate. N6 methylpurine (m6A) methylation regulates the tumor immune microenvironment. This study aimed to investigate the expression of m6A regulatory factor in PC and its relationship with prognosis.
methodsPC tissues and adjacent tissues were collected from PC patients who underwent surgical resection. The content of m6A regulator YTH m6A RNA binding protein 1 (YTHDF1) and insulin-like growth factor binding protein 2 (IGFBP2) was examined using Immunohistochemistry (IHC). The survival prognosis was predicted through Kaplan Meier survival curve. The patients were grouped into good and poor prognosis group according to whether recurrence and metastasis occurred within the 62 months of follow-up. Logistic regression analysis was adopted to analyze the risk factors.
resultsYTHDF1 and IGFBP2 were localized in the cytoplasm of PC tissues. The positive expression rate of YTHDF1 in cancer tissues was 69.81% (37/53), which was much higher than the 33.96% (18/53) in adjacent tissues (P < 0.01). The positive expression rate of IGFBP2 in cancer tissues was 62.26% (33/53), which was markedly higher than the 28.30% (15/53) in adjacent tissues (P < 0.01). The proportion of TNM stage III + IV, high Gleason score and PSA > 15 ng/mL was visibly higher in patients with positive expression of YTHDF1 than in patients with negative expression of YTHDF1 (P < 0.05). The proportion of TNM stage III + IV, high Gleason score and PSA > 15 ng/mL in IGFBP2 positive patients was sensibly higher than that in IGFBP2 negative patients (P < 0.05). YTHDF1 positive group had a median survival time of 35 months, which was evidently shorter than 44 months of YTHDF1 negative group (P < 0.05). The IGFBP2 positive group had a median survival time of 32 months, which was clearly shorter than 45 months of IGFBP2 negative group (P < 0.05). In addition, TNM stage, Gleason score, PSA, YTHDF1 and IGFBP2 were independent risk factors for poor prognosis of PC (P < 0.05).
conclusionsYTHDF1 and IGFBP2 were independent risk factors for poor prognosis of PC patients. They may be involved in the progression of prostate cancer, and serve as potential biomarkers for evaluating the prognosis of patients. However, its clinical translation value needs to be further verified by large sample and multi-center studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.